Lung Cancer Market – Highlights

The worldwide Lung Cancer Market is estimated to earn above USD 36928. 9 million by 2022. In terms of CAGR, the market is expected to develop at a healthy rate of up to 13.2% during the forecast period 2018-2022.

The growth of this market can be attributed to many factors. Some of the major ones include rising rate of lung cancer patients, the considerable growth of the geriatric population & increasing degree of healthcare expenditure.

New & improved developments can also be called as the drivers of the lung cancer market. Additional driving forces for the market include ever-growing environmental pollution & smoking. Even the passive smokers are vulnerable to lung cancer by 20 to 30%. Secondary growth drivers include exposure to radon gas & low immunity.

Emerging technological discoveries are considered as the most important growth drivers for the upcoming years.

Get Free Sample @ https://www.marketresearchfuture.com/sample_request/1185

Lung Cancer Market - Key Players

Prominent players at the forefront of competition in the Lung Cancer Market and are profiled in MRFR Analysis are:

• F. Hoffmann-La Roche Ltd (Switzerland)
• Novartis AG (Switzerland)
• Pfizer (US)
• Merck & Co., Inc. (US)
• Bristol-Myers Squibb (US)
• Eli Lilly and Company (US)
• Sanofi (France)

Lung Cancer Market - Segmentation

The Global Lung Cancer Market has been divided on the basis of types, treatments, end users & regions.

On the basis of types, the market is bifurcated into SCLC (Small Cell Lung Cancer) & NSCLC (Non-Small Cell Lung Cancer). SCLC typically originates in the cells that line the bronchi in the middle of the lungs. Cell carcinoma & combined cell carcinoma are the sub-segments of SCLC. NSCLC tends to affect the exterior region of the lung. This form of cancer is also referred to as adenocarcinoma. Sarcoma & Sarcomatoid carcinoma forms the sub-segments of NSCLC. SCLC held around 14.6% market shares back in 2015 whereas NSCLC earned above USD 1.298.8 million that year

On account of treatments, the market is fragmented into surgery, chemotherapy, radiotherapy, photodynamic therapy (PDT) & laser therapy. 

Hospitals & clinics, cancer research centers & laboratories form the end users. Amongst these, hospitals hold the largest market share.

Regionally, the market is segmented into North America, Europe, Asia Pacific, & Middle East & Africa & Rest Of The World.

Lung Cancer Market - Regional Analysis

The Global Lung Cancer Market spans across the regions of North America, Europe, Asia Pacific, and Middle East & Africa. North America is at the forefront of the global lung cancer market due to the presence of a well-developed healthcare sector, technological advances in healthcare and supportive government policies in the region. Europe is the second largest market for lung cancer and is expected to reach USD 8,536.3 Million by the end of 2023. Rising prevalence of lung cancer and extensive R&D activities for the development of drugs and therapies for lung cancer supports the growth of the market in Europe. Asia Pacific market is expected to gain prominence over the forecast period owing to rising expenditure and increasing focus on healthcare in the region. The Middle East & Africa market is expected to have a limited but steady growth over the forecast period.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
+1 646 845 9312
Email: salesteam@marketresearchfuture.com